TY - JOUR
T1 - VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface
AU - Eckford, Paul D.W.
AU - Ramjeesingh, Mohabir
AU - Molinski, Steven
AU - Pasyk, Stan
AU - Dekkers, Johanna F.
AU - Li, Canhui
AU - Ahmadi, Saumel
AU - Ip, Wan
AU - Chung, Timothy E.
AU - Du, Kai
AU - Yeger, Herman
AU - Beekman, Jeffrey
AU - Gonska, Tanja
AU - Bear, Christine E.
N1 - Funding Information:
These studies were supported by Operating Grants to C.E.B. from the Canadian Institutes of Health Research (CIHR MOP# 97954, CIHR GPG-102171) and Cystic Fibrosis Canada (CFC) as well as Operating Grants to H.Y. from CFC and a CIHR Investigator Award to T.G. J.B. obtained funding from the Dutch Cystic Fibrosis Society and the Wilhelmina Research Fund. P.D.W.E. was supported by fellowship awards through the CIHR and the CFC. S.P. was supported by a CFC Studentship Award. S.M. was supported by Peterborough K.M. Hunter and Ontario Graduate Studentships. Primary bronchial cultures generated from CF and non-CF lung transplant patients were provided through our collaboration with Dr. Shaf Keshavjee (Toronto Lung Transplant Program, University Health Network, with appropriate research ethics approval) and the University of Iowa Gene Therapy Center Cell Culture Core. We acknowledge the provision of corrector and inhibitor compounds from Dr. R. Bridges (Rosalind University) and distribution by the CFFT. We also acknowledge outstanding service by the Baylor Cell Culture Facility (National Institutes of Health grant P30 CA125123) in expressing Wt and mutant CFTR protein using the baculovirus system.
PY - 2014/5/22
Y1 - 2014/5/22
N2 - The most common mutation causing cystic fibrosis (CF), F508del, impairs conformational maturation of CF transmembrane conductance regulator (CFTR), thereby reducing its functional expression on the surface of epithelia. Corrector compounds including C18 (VRT-534) and VX-809 have been shown to partially rescue misfolding of F508del-CFTR and to enhance its maturation and forward trafficking to the cell surface. Now, we show that there is an additional action conferred by these compounds beyond their role in improving the biosynthetic assembly. In vitro studies show that these compounds bind directly to the metastable, full-length F508del-CFTR channel. Cell culture and patient tissue-based assays confirm that in addition to their cotranslational effect on folding, certain corrector compounds bind to the full-length F508del-CFTR after its partial rescue to the cell surface to enhance its function. These findings may inform the development of alternative compounds with improved therapeutic efficacy.
AB - The most common mutation causing cystic fibrosis (CF), F508del, impairs conformational maturation of CF transmembrane conductance regulator (CFTR), thereby reducing its functional expression on the surface of epithelia. Corrector compounds including C18 (VRT-534) and VX-809 have been shown to partially rescue misfolding of F508del-CFTR and to enhance its maturation and forward trafficking to the cell surface. Now, we show that there is an additional action conferred by these compounds beyond their role in improving the biosynthetic assembly. In vitro studies show that these compounds bind directly to the metastable, full-length F508del-CFTR channel. Cell culture and patient tissue-based assays confirm that in addition to their cotranslational effect on folding, certain corrector compounds bind to the full-length F508del-CFTR after its partial rescue to the cell surface to enhance its function. These findings may inform the development of alternative compounds with improved therapeutic efficacy.
UR - http://www.scopus.com/inward/record.url?scp=84901398808&partnerID=8YFLogxK
U2 - 10.1016/j.chembiol.2014.02.021
DO - 10.1016/j.chembiol.2014.02.021
M3 - Article
C2 - 24726831
AN - SCOPUS:84901398808
SN - 1074-5521
VL - 21
SP - 666
EP - 678
JO - Chemistry and Biology
JF - Chemistry and Biology
IS - 5
ER -